chevron_leftBack
Oncodesign Precision Medicine Société anonyme
ALOPM
0.4590EUR
3.4%
0.5289 USD
As of 7 June 2026, Oncodesign Precision Medicine Société anonyme has a market cap of $9.35M USD, ranking #41648 globally and #501 in France.
It ranks #3691 in the Healthcare sector, and #1200 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$9.35MUSD
8.05M EUR
Enterprise Value
$13.97MUSD
12.12M EUR
Revenue (TTM)
$2.02MUSD
1.74M EUR
EBITDA (TTM)
$7.47MUSD
6.48M EUR
Net Income (TTM)
$7.28MUSD
6.27M EUR
EBITDA Margin
373%
Profit Margin
361%
PE Ratio
1.3
PS Ratio
4.6
PB Ratio
0.8
EV/EBITDA
1.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Philippe Genne
open_in_new
Employees
14
Founded
1995
Website
oncodesign.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 3.4% | -7% | -12% | -24% | 11% | 15% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ALOPM
Oncodesign Precision Medicine SA
ISIN: FR001400CM63
Shares Out.:
Shares Outstanding:
19.087M1
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.4590 EUR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Oncodesign Precision Medicine Société anonyme
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company’s product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson’s disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers, as well as on developing treatment for pancreatic and other cancers. Oncodesign Precision Medicine Société anonyme was founded in 1995 and is based in Dijon, France.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EPA: SAN
|
$110.65B
1M%
95.26B EUR
|
19.9
|
|
EPA: IPN
|
$15.77B
169K%
13.58B EUR
|
31.1
|
|
EPA: NANO
|
$1.6B
17K%
1.37B EUR
|
-
|
|
EPA: DBV
|
$1.24B
13K%
1.07B EUR
|
-
|
|
EPA: VETO
|
$1.1B
12K%
949.55M EUR
|
16.6
|
|
EPA: MEDCL
|
$953.32M
10K%
820.77M EUR
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
8M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
6M%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
4M%
|
97.4
|
|
SIX: RO
|
$324.68B
3M%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$289.43B
3M%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$277.35B
3M%
218.9B CHF
|
20.5
|
chevron_leftBack